Hohnloser SH - Search Results

1

Effect of dronedarone on cardiovascular events in atrial fibrillation.

Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Hohnloser SH, et al. N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. N Engl J Med. 2009. PMID: 19213680 Free article. Clinical Trial.

2

Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation.

Hohnloser SH. Hohnloser SH. Pacing Clin Electrophysiol. 1994 May;17(5 Pt 2):1019-25. doi: 10.1111/j.1540-8159.1994.tb01456.x. Pacing Clin Electrophysiol. 1994. PMID: 7518589 Review.

3

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.

Hohnloser SH, van de Loo A, Baedeker F. Hohnloser SH, et al. J Am Coll Cardiol. 1995 Oct;26(4):852-8. doi: 10.1016/0735-1097(95)00286-5. J Am Coll Cardiol. 1995. PMID: 7560608 Free article. Clinical Trial.

4

Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.

Hohnloser SH, Meinertz T, Stubbs P, Crijns HJ, Blanc JJ, Rizzon P, Cheuvart B. Hohnloser SH, et al. Circulation. 1995 Sep 15;92(6):1517-25. doi: 10.1161/01.cir.92.6.1517. Circulation. 1995. PMID: 7664435 Clinical Trial.

5

Sotalol.

Hohnloser SH, Woosley RL. Hohnloser SH, et al. N Engl J Med. 1994 Jul 7;331(1):31-8. doi: 10.1056/NEJM199407073310108. N Engl J Med. 1994. PMID: 8202100 Review.

6

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.

Hohnloser SH, Singh BN. Hohnloser SH, et al. J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 2):920-36. doi: 10.1111/j.1540-8167.1995.tb00368.x. J Cardiovasc Electrophysiol. 1995. PMID: 8548113 Review.

7

Drug treatment of atrial fibrillation: what have we learned?

Hohnloser SH, Li YG. Hohnloser SH, et al. Curr Opin Cardiol. 1997 Jan;12(1):24-32. doi: 10.1097/00001573-199701000-00005. Curr Opin Cardiol. 1997. PMID: 9132077 Review.

8

Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial.

Hohnloser SH, Kuck KH. Hohnloser SH, et al. Pacing Clin Electrophysiol. 1997 Aug;20(8 Pt 1):1989-92. doi: 10.1111/j.1540-8159.1997.tb03606.x. Pacing Clin Electrophysiol. 1997. PMID: 9272538 Clinical Trial.

9

Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. Pharmacological Intervention in Atrial Fibrillation.

Hohnloser SH, Kuck KH. Hohnloser SH, et al. J Cardiovasc Electrophysiol. 1998 Aug;9(8 Suppl):S121-6. J Cardiovasc Electrophysiol. 1998. PMID: 9727686 Review.

10

Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.

Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN. Pacifico A, et al. Among authors: hohnloser sh. N Engl J Med. 1999 Jun 17;340(24):1855-62. doi: 10.1056/NEJM199906173402402. N Engl J Med. 1999. PMID: 10369848 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

552 results

Search Page

Filters